FDA Approves VYVANSE TM lisdexamfetamine Dimesylate , The First And Only Once-Daily Prodrug Stimulant To Treat ADHD In Adults
Added: 08 июня 2008
Last relative articles:
- Sensory Treatment Reduces Autistic Mannerisms
- VYVANSE Demonstrated Significant Improvement In ADHD Symptoms In Adults
- FDA Approves Strattera R For Maintenance Of ADHD In Children And Adolescents
- Simplicity Of Working Memory Study Could Help With ADD And Other Attention Difficulties
- New Analysis In Boys And Girls Shows The ADHD Patch, DAYTRANA TM methylphenidate Transdermal System , Offered ADHD Symptom Control For 12 Months
- OROS R Methylphenidate In Adults With ADHD: New Insights
- Shire Investigational Nonstimulant INTUNIV Showed Significant Efficacy In Reducing ADHD Symptoms
- New European Study Showed OROS R Methylphenidate Tablets Significantly Improved Symptoms In Adults With ADHD
- Increased Risk For Eating Disorders Found In Adolescent Girls With ADHD
- Studying ADHD In Youth Of Different Races
Comments: [0] / Post comment:
12 Nov 2008 18:55:25
Confirmation of HGT Business Day - 18th November 2008 - ITNews
Confirmation of HGT Business Day - 18th November 2008 ITNews, Italy - ... but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate ) (Attention Deficit Hyperactivity Disorder ("ADHD")); ...